1. What exactly is Retatrutide as a molecule?

Retatrutide is a synthetic peptide developed by Eli Lilly under the research code LY3437943. It is a triple receptor agonist — a single molecule that binds and activates three different receptors (GLP-1, GIP, and Glucagon) simultaneously. As of 2026 it is the most advanced multi-receptor compound in clinical development in the GLP-1 class, currently in Phase 3 trials under the TRIUMPH programme.

2. What is the molecular weight of Retatrutide?

Approximately 4.4 kDa, consistent with a 39-residue peptide with fatty-acid acylation. The exact structural details — including the C20 fatty-diacid acylation and Aib substitutions that confer DPP-4 resistance — are documented in Coskun et al., Cell Metabolism 2022 (DOI 10.1016/j.cmet.2022.07.013).

3. Who developed Retatrutide?

Eli Lilly & Company. The compound was designed by Lilly's peptide chemistry group as the first triple receptor agonist (GLP-1 + GIP + Glucagon) to reach human clinical trials. The Phase 2 dose-finding obesity trial was led by Ania Jastreboff (Yale) and colleagues and published in the New England Journal of Medicine in June 2023.

4. When was Retatrutide first publicly described?

The original receptor-binding characterisation and Phase 1 pharmacokinetic profile were published by Coskun et al. in Cell Metabolism in 2022. The pivotal Phase 2 obesity trial published in NEJM in June 2023. Both are accessible via the research papers index .

5. Is Retatrutide a single peptide or a blend?

A single peptide. Retatrutide is one engineered molecule with three receptor-binding domains — not a combination of three separate compounds. The triple-agonism is achieved by a single peptide sequence that interacts with all three receptors simultaneously, which is fundamentally different from administering a blend of GLP-1 + GIP + glucagon agonists separately.

6. What three receptors does Retatrutide target?

GLP-1R (Glucagon-Like Peptide-1 Receptor), GIPR (Glucose-dependent Insulinotropic Polypeptide Receptor), and GcgR (Glucagon Receptor). All three are Class B G-protein-coupled receptors. The triple-agonism is the mechanistic basis for the compound's effects on appetite suppression, insulin sensitisation, and hepatic thermogenesis.

7. How does GLP-1 receptor agonism contribute to Retatrutide's effects?

GLP-1R is expressed in pancreatic alpha and beta cells, hypothalamic appetite-regulatory neurons, brainstem nuclei (mediating nausea responses), and gastric tissue. Agonism drives glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety centrally. This is the same receptor mechanism engaged by Semaglutide and the GLP-1 component of Tirzepatide.

8. How does GIP receptor agonism contribute?

GIPR co-agonism alongside GLP-1R produces additive insulin secretion through pathways distinct from GLP-1R, modulates adipose tissue lipid handling, and appears to dampen the GI adverse-event signal that GLP-1R agonism alone produces. This is the design innovation that produced Tirzepatide's SURMOUNT-1 outcomes versus Semaglutide STEP 1 — Retatrutide carries that benefit forward and adds the third receptor on top.

9. How does Glucagon receptor agonism contribute?

GcgR agonism is the third receptor target, unique to Retatrutide among the three primary research-grade GLP-1 class peptides. Activation in hepatic and adipose tissue drives fatty-acid oxidation, lipolysis, and thermogenic gene expression. The result is increased resting energy expenditure — an energy-OUTPUT mechanism on top of the energy-INPUT-reducing mechanisms of GLP-1R/GIPR.

10. Why doesn't Glucagon receptor agonism cause hyperglycaemia?

In isolation, glucagon receptor agonism would raise blood glucose — glucagon's classical role is hepatic gluconeogenesis. Retatrutide's design balances this: the simultaneous GLP-1R co-agonism drives glucose-dependent insulin secretion that offsets the glucagon-receptor glucose-raising effect. Net glycaemic effect in Phase 2 was glucose-lowering, not glucose-raising — the thermogenic benefit of GcgR is captured without the glycaemic downside.

11. What is the receptor binding affinity of Retatrutide?

Detailed binding affinities (Ki and EC50 values for GLP-1R, GIPR, and GcgR) are published in Coskun et al., Cell Metabolism 2022. Retatrutide is more potent at GLP-1R than at GcgR by approximately one order of magnitude, with intermediate GIPR affinity — this affinity gradient is part of the design that keeps the glucagon receptor mechanism in balance.

12. How does Retatrutide's mechanism differ from Tirzepatide?

Tirzepatide is a dual GLP-1/GIP agonist — two receptor targets, neither engaging the Glucagon receptor. Retatrutide adds GcgR as a third target. The mechanistic consequence is that Retatrutide gains a thermogenic / hepatic fat-oxidation pathway that Tirzepatide does not engage. Phase 2 outcomes are consistent with this mechanistic addition producing additive weight reduction.

13. How does Retatrutide's mechanism differ from Semaglutide?

Semaglutide is a single GLP-1R agonist. Retatrutide adds two more receptor targets (GIPR and GcgR), each contributing distinct downstream effects. Semaglutide produces appetite suppression and insulin secretion via GLP-1R alone; Retatrutide produces those effects plus GIPR-mediated insulin amplification and GcgR-mediated thermogenesis.

14. What was the Phase 2 Retatrutide trial design?

Randomised, double-blind, placebo-controlled trial in 338 adults with obesity (BMI ≥30, or ≥27 with at least one weight-related comorbidity, without type 2 diabetes) over 48 weeks. Six cohorts: placebo, 1mg, 4mg slow titration, 4mg fast titration, 8mg, 12mg weekly subcutaneous. NCT04881760. Primary endpoint: percentage change in body weight at 48 weeks. Published in NEJM 28 June 2023 (DOI 10.1056/NEJMoa2301972).

15. What was the primary endpoint?

Percentage change in body weight from baseline at the 48-week primary endpoint. Secondary endpoints included weight change at 24 weeks, percentage of participants achieving ≥5%/≥10%/≥15% weight reduction, change in waist circumference, change in fasting insulin and triglycerides, change in liver fat fraction on MRI in a measured subset, and safety/tolerability outcomes.

16. What was the highest weight loss observed in Phase 2?

24.2% mean body weight reduction at the 12mg/week cohort over 48 weeks (placebo-adjusted ~22.1%). This is the highest single mean weight-loss endpoint reported for any GLP-1-class compound in research to date. The 8mg cohort achieved 22.8%, the 4mg fast-titration cohort 17.3%, the 4mg slow-titration cohort 12.9%, the 1mg cohort 8.7%, and placebo 2.1%.

17. Were lower doses also effective?

Yes — meaningfully so. The 1mg/week cohort (a single-step initiation with no escalation) still produced 8.7% mean weight loss at 48 weeks, vs 2.1% for placebo. This demonstrates clinically meaningful activity even at sub-maximal doses. The dose-response curve was approximately linear from 1mg through 8mg, with the 12mg cohort producing modest incremental gain over 8mg.

18. What were the secondary metabolic endpoints?

At the 12mg cohort over 48 weeks: approximately 41% mean reduction in fasting insulin, approximately 43% mean reduction in triglycerides, approximately 18.5 cm mean reduction in waist circumference, and a meaningful reduction in liver fat fraction on MRI in the measured subset. Cardiometabolic biomarkers including HbA1c, LDL cholesterol, and blood pressure also improved across active-treatment cohorts.

19. What was the dose escalation schedule?

All active cohorts initiated at 2mg/week and stepped up at 4-week intervals. The 4mg cohort reached 4mg at week 5. The 8mg cohort escalated 2→4→6→8 mg with maintenance from week 13. The 12mg cohort escalated 2→4→8→10→12 mg with maintenance from week 17. The 1mg cohort dosed at 1mg/week throughout with no escalation.

20. Where was the Phase 2 trial conducted?

Multi-centre, primarily United States enrolment sites. Trial registration on ClinicalTrials.gov (NCT04881760) lists the full investigator and site list. The Phase 3 TRIUMPH programme has expanded geographic coverage significantly, including Australian sites at the University of Sydney Boden Initiative for TRIUMPH-3.

21. Has Phase 2 retatrutide been replicated in type 2 diabetes?

Yes. Rosenstock et al., The Lancet 2023 (DOI 10.1016/S0140-6736(23)01053-X) reported a separate Phase 2 trial of retatrutide in adults with type 2 diabetes, comparing retatrutide doses against placebo and the active comparator dulaglutide 1.5mg. HbA1c reductions exceeded the active comparator at the higher retatrutide doses; weight loss was significantly greater than with dulaglutide.

22. What is the TRIUMPH programme?

TRIUMPH is Eli Lilly's Phase 3 development plan for Retatrutide. As of 2026 it includes TRIUMPH-1 (obesity, ~2,200 enrolled), TRIUMPH-2 (obesity with sleep apnoea, ~675), TRIUMPH-3 (obesity + cardiovascular disease, ~1,800), TRIUMPH-4 (adolescent obesity, ~600), TRIUMPH-NAFLD (MASH liver disease, ~700), and SYNERGY-OUTCOMES (cardiovascular outcomes MACE, ~17,000+). See the Phase 3 update for current status.

23. When will TRIUMPH Phase 3 results be available?

Primary endpoint readouts for TRIUMPH-1 and TRIUMPH-3 are anticipated in late 2026 to mid-2027 per Eli Lilly investor guidance. SYNERGY-OUTCOMES (cardiovascular outcomes) follows a longer timeline through 2028. TRIUMPH-2, TRIUMPH-4, and TRIUMPH-NAFLD will report on staggered timelines through the same window.

24. Are Australian sites participating in TRIUMPH?

Yes. TRIUMPH-3 (obesity + cardiovascular disease, NCT05882077) lists the University of Sydney Boden Initiative as an active enrolment site. SYNERGY-OUTCOMES (NCT06077864) has multiple Australian cardiology centres participating. Other TRIUMPH studies have selected Australian sites.

25. What is SYNERGY-OUTCOMES?

SYNERGY-OUTCOMES (NCT06077864) is the cardiovascular outcomes trial for retatrutide — a ~17,000+ participant multi-centre study evaluating MACE (major adverse cardiovascular events: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke). It is the cardiovascular-outcomes parallel to Semaglutide's SELECT trial. Timeline extends through 2028.

26. What is TRIUMPH-NAFLD?

TRIUMPH-NAFLD (NCT06324877) is the Phase 3 trial of retatrutide in adults with MASH/MASLD (metabolic dysfunction-associated steatotic liver disease). It follows from positive Phase 2a outcomes published in Sanyal et al., Nature Medicine 2024. ~700 participants. Liver fat fraction reduction on MRI plus histological endpoints.

27. Why TRIUMPH-2 specifically for sleep apnoea?

Obstructive sleep apnoea is a high-prevalence comorbidity in obesity. Tirzepatide's SURMOUNT-OSA trial demonstrated significant reduction in apnoea-hypopnoea index alongside weight loss; TRIUMPH-2 tests whether retatrutide produces a comparable or stronger effect, given the deeper weight loss seen in retatrutide Phase 2. NCT05882049, ~675 participants.

28. How much larger is TRIUMPH than Phase 2?

The Phase 2 obesity trial enrolled 338 adults. The Phase 3 TRIUMPH programme spans 22,000+ participants across six trials. TRIUMPH-1 alone (~2,200) is approximately 6.5× the Phase 2 enrolment. SYNERGY-OUTCOMES (~17,000+) is approximately 50× larger. The expansion reflects the cardiovascular-safety regulatory requirements for therapeutic approval pathways in non-research contexts.

29. How does Retatrutide compare to Tirzepatide in weight-loss outcomes?

Cross-trial comparison (different populations, durations, doses — not head-to-head): Retatrutide Phase 2 reported 24.2% mean weight loss at 12mg/week over 48 weeks. Tirzepatide SURMOUNT-1 reported 20.9% at 15mg/week over 72 weeks. Retatrutide achieved its endpoint approximately 24 weeks earlier than Tirzepatide's comparator endpoint. See full Retatrutide vs Tirzepatide .

30. How does Retatrutide compare to Semaglutide?

Cross-trial: Retatrutide Phase 2 reported 24.2% mean weight loss at 12mg/week over 48 weeks. Semaglutide STEP 1 reported 14.9% at 2.4mg/week over 68 weeks. The two compounds differ substantially in receptor mechanism (Semaglutide is single GLP-1R; Retatrutide is triple GLP-1R/GIPR/GcgR). See full Retatrutide vs Semaglutide .

31. What mechanistically explains Retatrutide's superior Phase data?

The Glucagon receptor (GcgR) co-agonism is the mechanistic addition unique to Retatrutide. Where Semaglutide and Tirzepatide reduce energy intake (appetite suppression + reduced gastric emptying), Retatrutide adds an energy-expenditure pathway via hepatic fat oxidation and thermogenesis. The dual-sided intervention (input reduction + output increase) is the proposed driver of additive weight reduction beyond dual agonism.

32. Does Retatrutide preserve more lean mass than other GLP-1s?

The hypothesis is plausible — GcgR-mediated fat oxidation could reduce reliance on muscle protein catabolism to meet the caloric deficit. Phase 2 body composition data is consistent with a high fat-mass fraction of weight lost. However, no direct head-to-head body composition trial exists, and a 2026 preclinical MC4R mouse model found no significant lean mass difference across the three compounds. Phase 3 data will be the definitive test.

33. How does Retatrutide compare to Cagrilintide?

Cagrilintide is a long-acting amylin analogue, mechanistically distinct from the GLP-1 class. Cagrilintide is being studied both alone and in combination with semaglutide (CagriSema). Retatrutide and Cagrilintide are not direct mechanistic competitors — different receptor targets, different research questions. No head-to-head trial exists.

34. How does Retatrutide compare to Survodutide?

Survodutide (BI 456906) is a dual GLP-1/Glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma — mechanistically the dual-agonist parallel to Retatrutide's triple-agonism. Survodutide engages GLP-1R + GcgR but not GIPR. Phase 2 obesity outcomes published in 2024 reported comparable weight loss to Tirzepatide at maximum dose. Retatrutide and Survodutide differ in whether GIPR is engaged.

35. Is there a head-to-head trial of Retatrutide vs Tirzepatide?

No. Both compounds are developed by the same company (Eli Lilly), creating commercial-cannibalisation disincentive for a direct comparison. All Retatrutide-vs-Tirzepatide comparisons in the research literature are cross-trial, drawn from separate studies with different populations, durations, and dose ranges. Phase 3 TRIUMPH outcomes will clarify Retatrutide's position relative to the established Tirzepatide benchmark.

36. What is the half-life of Retatrutide?

Approximately 6 days, derived from Phase 1 pharmacokinetic data (Coskun et al., Cell Metabolism 2022). This supports once-weekly subcutaneous dosing — the schedule used throughout Phase 2 and the Phase 3 TRIUMPH programme. The extended half-life is achieved through fatty-diacid acylation enabling albumin binding (similar to semaglutide and tirzepatide).

37. What is the time to maximum plasma concentration (Tmax)?

Approximately 24–72 hours post subcutaneous injection. Peak plasma concentration follows the standard absorption profile of fatty-acid-acylated GLP-1 class peptides — slower than non-acylated short-acting compounds but consistent with sustained albumin-bound circulation supporting once-weekly dosing.

38. When does Retatrutide reach steady state?

Approximately 4–5 weeks of consistent weekly subcutaneous dosing. Steady-state plasma concentration is the regime where weekly clearance equals weekly dose input. The 4-week dose-escalation steps used in Phase 2 are partly designed around this kinetic — each escalation step is held long enough for the new steady state to establish before assessing tolerability.

39. How is Retatrutide eliminated?

Primarily through peptide hydrolysis by endogenous proteases (similar to other large peptide therapeutics). The fatty-diacid acylation slows DPP-4 cleavage but does not eliminate proteolytic degradation entirely. Both renal and non-renal clearance pathways contribute. Specific clearance distribution is documented in the Phase 1 PK paper (Coskun et al. 2022).

40. Does food affect Retatrutide absorption?

Subcutaneous administration bypasses GI absorption entirely, so direct food-effect on the peptide bioavailability is minimal. Indirect food-related effects on weight outcomes (caloric intake reduction is part of the mechanism) are confounded by the active appetite-suppression pharmacology rather than absorption kinetics. Phase 2 protocols did not require fasted-state dosing.

41. How should Retatrutide be reconstituted?

Lyophilised Retatrutide is reconstituted with bacteriostatic water (0.9% benzyl alcohol in sterile water). The standard 10mg/mL working concentration uses 1.0mL bac water for a 10mg vial, 2.0mL for 20mg, 3.0mL for 30mg. Inject slowly down the inner wall, swirl gently (do not shake), store at 2–8°C. See the full reconstitution protocol .

42. What concentration should be targeted?

Most research protocols target 10mg/mL — the standard across the GLP-1 research peptide range, chosen because it simplifies cross-vial dose calculation (1mg = 0.1mL = 10 units on a U100 insulin syringe). Higher concentrations (15mg/mL or 20mg/mL) are used for protocols requiring smaller injection volumes; lower concentrations for very-low-dose research arms.

43. How long is reconstituted Retatrutide stable?

Approximately 4 weeks when stored refrigerated at 2–8°C. The bacteriostatic water diluent's 0.9% benzyl alcohol preservative supports multi-week multi-withdrawal use. Do not freeze the reconstituted solution — freeze-thaw cycling promotes peptide aggregation and is the primary degradation pathway for liquid peptide solutions.

44. Should lyophilised Retatrutide be stored frozen?

Lyophilised peptide is most stable at −20°C, protected from light and moisture. Refrigerated (2–8°C) storage of the unopened lyophilised vial is acceptable short-term but −20°C is the long-term storage condition. Once reconstituted, refrigerate at 2–8°C and use within 4 weeks; do not freeze the reconstituted solution.

45. What syringe is appropriate for dose draws?

A standard U100 insulin syringe (0.3mL, 0.5mL, or 1mL barrel) is the most common research-protocol choice at 10mg/mL working concentration. The U100 graduation means 100 units = 1mL = 10mg at the standard concentration. For very-low-dose cohorts (e.g. 0.5mg or 1mg doses, requiring sub-15-unit volumes), a 0.3mL low-dead-space syringe gives the best volume precision.

46. What are the most common adverse events in Phase 2?

GI events dominate. At the 12mg cohort over 48 weeks: nausea ~42%, vomiting ~20%, diarrhoea ~18%, constipation ~14%, decreased appetite in the majority of subjects, injection site reactions ~8%. Events were dose-dependent and concentrated in the early dose-escalation weeks. See full side-effects breakdown .

47. What is the rate of nausea at the highest dose?

Approximately 42% of the 12mg cohort experienced nausea over 48 weeks, vs ~13% for placebo. Nausea was dose-dependent across cohorts: ~14% at 1mg, ~22% at 4mg slow-titration, ~32% at 4mg fast-titration, ~36% at 8mg. Events were concentrated in the early titration window (weeks 1–12) and typically resolved with continued dosing or transient dose-step pauses.

48. Were pancreatitis or thyroid C-cell tumours reported in Phase 2?

No. No cases of pancreatitis, thyroid C-cell tumours, or severe hypoglycaemia were reported in any retatrutide cohort during the 48-week Phase 2 trial. Long-term safety beyond 48 weeks is being characterised in the ongoing Phase 3 TRIUMPH programme — the SYNERGY-OUTCOMES trial in particular collects multi-year safety data across a 17,000+ participant cohort.

49. What was the discontinuation rate in Phase 2?

In the 12mg cohort: approximately 6.4% AE-driven discontinuation and approximately 22% all-cause discontinuation over 48 weeks. The 8mg cohort showed ~6.3% AE-driven, ~21% all-cause. Lower-dose cohorts (1mg, 4mg) showed 4.5–4.7% AE-driven discontinuation. Most AE-driven discontinuations occurred during the early titration window and were attributed to GI events.

50. How long do GI adverse events typically last?

Phase 2 data showed dose-dependent GI events concentrated in the first 12 weeks of treatment, coinciding with dose escalation. Most events resolved with continued dosing, dose-step pauses, or anti-emetic co-administration. Persistent grade 3+ GI events leading to discontinuation occurred in approximately 6.4% of the maximum-dose cohort over the full 48-week trial. Phase 3 TRIUMPH outcomes will provide larger-cohort data on long-term tolerability.

All Research

Retatrutide FAQ: 50 Research Questions Answered

50 research-oriented questions about Retatrutide answered with primary-source citations. Covers receptor mechanism, Phase 2 trial design and outcomes, the TRIUMPH Phase 3 programme, cross-compound comparison with Tirzepatide and Semaglutide, pharmacokinetic profile, reconstitution protocol, and the Phase 2 adverse event signal.

By RetaLABS Research Team·18 min read·Updated 25 May 2026

RetaLABS stocks Retatrutide — research-grade, fast AU shipping, discreet packaging.

View Retatrutide →

About This FAQ

50 questions covering the breadth of current Retatrutide research as of 2026, organised into eight thematic sections. Designed for researchers, AI search engines, and detail-oriented readers — every numerical claim is sourced to the primary peer-reviewed publication.

For shorter, customer-facing questions about ordering and basic compound facts, see the general FAQ. For the primary-source citation list underlying the answers below, see the Retatrutide Research Papers index. For mechanism depth on each receptor target, see the entity pages: GLP-1 Explained, GIP Receptor Explained, Glucagon Receptor Explained.

Source Research-Grade Retatrutide in Australia

Research-grade. Fast Australia-wide shipping. Discreet packaging. Crypto payments accepted.

View Retatrutide →

More Research Guides

Retatrutide Australia 2026: Research Guide, Mechanism, Trial Data & Reconstitution

15 min read

→

Retatrutide Dosing Protocol: Phase 2 Trial Reference for Researchers

8 min read

→

Retatrutide Statistics 2026: Trial Numbers, Dose-Cohort Data & Phase 3 Enrollment

9 min read

→

View all research →